Robert Lanza, Chief Scientific Officer at ADVANCED CELL TECHNOLOGY, INC. (ACTC), sold 600,000 shares at $0.07 ($42K) on 2010-07-20, disclosed to the SEC on 2010-07-23.
Open-market sale of $42k ACTC by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.07 | 5,000 | $350 | 0.8% |
| 2 | $0.07 | 5,550 | $389 | 0.9% |
| 3 | $0.07 | 17,000 | $1K | 2.8% |
| 4 | $0.07 | 18,900 | $1K | 3.2% |
| 5 | $0.07 | 34,700 | $2K | 5.8% |
| 6 | $0.07 | 160,300 |
| $11K |
| 26.7% |
| 7 | $0.07 | 255,700 | $18K | 42.6% |
| 8 | $0.07 | 102,850 | $7K | 17.1% |
| Total | $0.07 avg | 600,000 | $42K | 100% |
| Filing → |
| ACTC | SELL | 2012-12-18 | $80K | — | Filing → |
| ACTC | SELL | 2012-08-01 | $160K | — | Filing → |
| ACTC | SELL | 2012-01-25 | $1.4M | — | Filing → |